• Amir Goodarzi, Bart Thaci, Atrin Toussi, Tejas Karnati, Kee Kim, and Ruben Fragoso.
• Department of Neurological Surgery, University of California, Davis, School of Medicine, Sacramento, California, USA. Electronic address: agoodarzi@ucdavis.edu.
• World Neurosurg. 2019 Apr 1; 124: 101109101-109.

AbstractPrimary spinal glioblastoma multiforme (GBM) of the conus medullaris is a rare and devastating pathologic entity. The presenting symptoms commonly include progressive neurologic deficits in the lower extremities, bowel and bladder dysfunction, and low back pain. Histologically, these tumors have high-grade features similar to their intracranial counterparts. However, recent advancements in the field of molecular oncology have been beginning to elucidate a unique molecular blueprint for these spinal gliomas. Given the lack of standardized treatment strategies, we have presented our institutional experience in treating a small series of patients with conus medullaris GBM and have reviewed the reported data on the relevant molecular markers, management strategies, and complication avoidance for this malignant pathologic entity.Copyright © 2019 Elsevier Inc. All rights reserved.

5 keywords...

hide…